VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
- PMID: 12087404
- DOI: 10.1038/nature00821
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
Abstract
Vascular endothelial growth factor (VEGF) is a principal regulator of blood vessel formation and haematopoiesis, but the mechanisms by which VEGF differentially regulates these processes have been elusive. Here we describe a regulatory loop by which VEGF controls survival of haematopoietic stem cells (HSCs). We observed a reduction in survival, colony formation and in vivo repopulation rates of HSCs after ablation of the VEGF gene in mice. Intracellularly acting small-molecule inhibitors of VEGF receptor (VEGFR) tyrosine kinase dramatically reduced colony formation of HSCs, thus mimicking deletion of the VEGF gene. However, blocking VEGF by administering a soluble VEGFR-1, which acts extracellularly, induced only minor effects. These findings support the involvement in HSC survival of a VEGF-dependent internal autocrine loop mechanism (that is, the mechanism is resistant to inhibitors that fail to penetrate the intracellular compartment). Not only ligands selective for VEGF and VEGFR-2 but also VEGFR-1 agonists rescued survival and repopulation of VEGF-deficient HSCs, revealing a function for VEGFR-1 signalling during haematopoiesis.
Similar articles
-
Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.Cancer Res. 2001 Oct 1;61(19):7002-8. Cancer Res. 2001. PMID: 11585724
-
Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.Cancer. 2000 Aug 1;89(3):488-99. Cancer. 2000. PMID: 10931447
-
Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.J Pharmacol Exp Ther. 2001 Dec;299(3):1073-85. J Pharmacol Exp Ther. 2001. PMID: 11714897
-
VEGF receptor signaling and endothelial function.IUBMB Life. 2001 Jul;52(1-2):61-6. doi: 10.1080/15216540252774784. IUBMB Life. 2001. PMID: 11795595 Review.
-
The biology of VEGF and its receptors.Nat Med. 2003 Jun;9(6):669-76. doi: 10.1038/nm0603-669. Nat Med. 2003. PMID: 12778165 Review.
Cited by
-
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.Br J Haematol. 2018 Feb;180(3):445-448. doi: 10.1111/bjh.14333. Epub 2016 Sep 21. Br J Haematol. 2018. PMID: 27650362 Free PMC article. Clinical Trial. No abstract available.
-
Hematopoietic Stem Cells and Their Niche in Bone Marrow.Int J Mol Sci. 2024 Jun 21;25(13):6837. doi: 10.3390/ijms25136837. Int J Mol Sci. 2024. PMID: 38999948 Free PMC article. Review.
-
Activation of diverse signaling pathways by ex-vivo delivery of multiple cytokines for myocardial repair.Stem Cells Dev. 2013 Jan 15;22(2):204-15. doi: 10.1089/scd.2011.0575. Epub 2012 Oct 5. Stem Cells Dev. 2013. PMID: 22873203 Free PMC article.
-
Placental hypoxia, endoplasmic reticulum stress and maternal endothelial sensitisation by sFLT1 in pre-eclampsia.J Reprod Immunol. 2016 Apr;114:81-5. doi: 10.1016/j.jri.2015.07.004. Epub 2015 Jul 18. J Reprod Immunol. 2016. PMID: 26228018 Free PMC article.
-
Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1.Mol Cell Biol. 2013 Oct;33(19):3762-79. doi: 10.1128/MCB.01570-12. Epub 2013 Jul 22. Mol Cell Biol. 2013. PMID: 23878397 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases